MiMedx Group, Inc.

MiMedx develops and distributes placental tissue allografts for wound care, burn, and surgical applications. The company processes human placental tissues, including the membrane, umbilical cord, and placental disc, using its patented PURION process. This method produces allografts that retain the tissue's natural biological properties and regulatory proteins such as cytokines, chemokines, and growth factors. Their wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets, which serve as protective barriers for wounds. For surgical use, they offer AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT, used in lower extremity repair, plastic surgery, vascular surgery, and orthopedic repairs. The company also has a strategic alliance with Vaporox, Inc. to promote their wound care offerings.

MiMedx Group is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol MDXG. The company operates in the United States and its financials are reported in US Dollars (USD). As a US-based company trading on a US exchange, its stock is traded in USD, making it accessible to investors through standard brokerage accounts that support Nasdaq listings.

MiMedx Group operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing and commercializing regenerative tissue products derived from human placental tissues. The company's work involves processing biological materials to create allografts that aid in wound healing and surgical repair, which falls under the broader biotechnology umbrella. This industry is characterized by research-intensive processes and regulatory oversight, and MiMedx's patented PURION processing method is a key differentiator in producing allografts that retain natural biological properties.

MiMedx Group is headquartered in Marietta, Georgia, United States. The company was founded in 2006 and primarily serves the US market. It sells its products through a direct sales force and independent sales agents, as well as to individual customers and independent distributors within the United States. While the company's operations are focused domestically, its products address various healthcare sectors including wound care, burn treatment, and surgical fields such as lower extremity repair, plastic surgery, vascular surgery, and orthopedic reconstructions. The company's strategic alliance with Vaporox, Inc. also supports the promotion of their wound care offerings in the US.

MiMedx generates revenue by developing and distributing placental tissue allografts for use in wound care, burn, and surgical applications. The company processes human placental tissues using its patented PURION method to produce allografts that retain biological properties. Their product portfolio includes wound care products like EPIFIX, EPICORD, and CHORIOFIX, as well as surgical products such as AMNIOFIX and AMNIOBURN. Revenue is derived from selling these products through a direct sales force, independent sales agents, and distributors in the United States. The company also has a strategic alliance with Vaporox, Inc., which may contribute to revenue through joint promotion of wound care offerings. By targeting multiple healthcare segments, MiMedx aims to capture value from both chronic wound management and surgical procedures.